MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F23%3A73623349" target="_blank" >RIV/61989592:15110/23:73623349 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/23:10158267

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.14440" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/resp.14440</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/resp.14440" target="_blank" >10.1111/resp.14440</a>

Jazyk výsledku

angličtina

Název v původním jazyce

MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis

Popis výsledku v původním jazyce

Background and Objective: The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients. Methods: In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed. Results: In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged &lt;56 year, to 63% in patients aged &gt;75. In IPF patients aged &lt;56, the MUC5B minor allele was not associated with survival. In IPF patients aged &gt;= 56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 x 10(-12)). Conclusion: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.

Název v anglickém jazyce

MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis

Popis výsledku anglicky

Background and Objective: The minor T-allele of the MUC5B promoter polymorphism rs35705950 is strongly associated with idiopathic pulmonary fibrosis (IPF). However, conflicting results have been reported on the relationship between the MUC5B minor allele and survival and it is unknown whether a specific subgroup of IPF patients might benefit from MUC5B minor allele carriage. We investigated the association between MUC5B rs35705950, survival and patient characteristics in a real-world population of European IPF patients. Methods: In this retrospective study, 1751 patients with IPF from 8 European centres were included. MUC5B rs35705950 genotype, demographics, clinical characteristics at diagnosis and survival data were analysed. Results: In a multi-variate Cox proportional hazard model the MUC5B minor allele was a significant independent predictor of survival when adjusted for age, sex, high resolution computed tomography pattern, smoking behaviour and pulmonary function tests in IPF. MUC5B minor allele carriers were significantly older at diagnosis (p = 0.001). The percentage of MUC5B minor allele carriers increased significantly with age from 44% in patients aged &lt;56 year, to 63% in patients aged &gt;75. In IPF patients aged &lt;56, the MUC5B minor allele was not associated with survival. In IPF patients aged &gt;= 56, survival was significantly better for MUC5B minor allele carriers (45 months [CI: 42-49]) compared to non-carriers (29 months [CI: 26-33]; p = 4 x 10(-12)). Conclusion: MUC5B minor allele carriage associates with a better median transplant-free survival of 16 months in the European IPF population aged over 56 years. MUC5B genotype status might aid disease prognostication in clinical management of IPF patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

<a href="/cs/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molekulární, buněčný a klinický přístup ke zdravému stárnutí</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

RESPIROLOGY

ISSN

1323-7799

e-ISSN

1440-1843

Svazek periodika

28

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

AU - Austrálie

Počet stran výsledku

10

Strana od-do

455-464

Kód UT WoS článku

000903699500001

EID výsledku v databázi Scopus

2-s2.0-85149541135